Industries de la santé
01 Septembre 2011
HAIFA, ISRAEL, August 25, 2011 -- Pluristem Therapeutics, Inc. (NASDAQ:PSTI; TASE:PLTR) today announced that on August 22, 2011 the U.S. Food and Drug Administration (FDA) designated Pluristem’s PLX cells orphan status for the treatment of thromboangiitis obliterans (Buerger's disease). The Company also announced that a concurrent application in Europe at the EMA’s Committee for Orphan... |